<?xml version="1.0" encoding="UTF-8"?>
<p>To combat drug resistance, there are two main strategies: (1) Drugs with novel modes of action to bypass resistance to established drugs or (2) inhibitors of resistance mechanisms for resensitization of tumor cells [
 <xref rid="B8-biomolecules-10-00817" ref-type="bibr">8</xref>]. The most general approach has been the development of P-glycoprotein (P-gp) inhibitors to co-administer with anticancer drugs [
 <xref rid="B6-biomolecules-10-00817" ref-type="bibr">6</xref>]. This consists of the pharmacological blockage of drug transporters such as P-gp (a type of ABC transporter) [
 <xref rid="B8-biomolecules-10-00817" ref-type="bibr">8</xref>], that can lower intracellular drug concentration by expelling the drug from cancer cells [
 <xref rid="B5-biomolecules-10-00817" ref-type="bibr">5</xref>]. However, despite their great in vitro success, there is no P-gp inhibitor currently available for clinical use [
 <xref rid="B6-biomolecules-10-00817" ref-type="bibr">6</xref>].
</p>
